Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

43.99USD
4:01pm EDT
Price Change (% chg)

$0.75 (+1.73%)
Prev Close
$43.24
Open
$43.74
Day's High
$44.22
Day's Low
$43.46
Volume
1,984,142
Avg. Vol
2,582,179
52-wk High
$49.57
52-wk Low
$30.64

BMY.N

Chart for BMY.N

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities... (more)

Overall

Beta: 0.39
Market Cap (Mil.): $71,187.03
Shares Outstanding (Mil.): 1,646.32
Dividend: 0.35
Yield (%): 3.24

Financials

  BMY.N Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -- -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

CORRECTED-UPDATE 1-U.S. FDA puts hold on Vertex hepatitis study

(Corrects third paragraph to show hold on U.S. trial, not European study)

25 Jul 2013

U.S. FDA puts hold on Vertex hepatitis study; shares fall

- Vertex Pharmaceuticals Inc said U.S. health regulators placed a partial clinical hold on its mid-stage study of an experimental oral hepatitis C treatment because of potential liver problems, sending its shares sharply lower on Thursday.

25 Jul 2013

UPDATE 2-Bristol cuts forecast, new blood clot drug struggles

July 25 - U.S. drugmaker Bristol-Myers Squibb Co cut its full-year revenue and earnings forecasts and posted disappointing sales of its new drug to prevent blood clots and its once-weekly Bydureon diabetes drug.

25 Jul 2013

Fitch Downgrades Bristol Myers Squibb's IDR to 'A-'; Outlook to Stable

(The following statement was released by the rating agency) CHICAGO, July 01 (Fitch) Fitch Ratings has downgraded Bristol-Myers Squibb Co.'s (Bristol Myers Squibb) long-term Issuer Default Rating (IDR) to 'A-' from 'A'. See a full list of affected ratings below. The ratings apply to approximately $7.3 billion of debt. The Rating Outlook is revised to Stable from Negative. KEY RATING DRIVERS --Operational pressure peaking in 2013: Plavix and Avapro patent expirations have negatively affect

01 Jul 2013

Release of Eliquis blood clot preventer story

The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused far less bleeding, according to data from a large clinical trial.

30 Jun 2013

UPDATE 2-Astra, Bristol diabetes drug disappoints in key test

LONDON, June 19 - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.

19 Jun 2013

AstraZeneca, Bristol diabetes drug disappoints in key test

LONDON - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.

19 Jun 2013

UPDATE 1-Former Bristol-Myers executive admits to insider trading

* Defendant accused of buying options in takeover targets

10 Jun 2013

Former Bristol-Myers executive admits to insider trading

- A former Bristol-Myers Squibb Co finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was preparing to buy.

10 Jun 2013

Former Bristol-Myers executive admits to insider trading

* Defendant accused of buying options in takeover targets

10 Jun 2013

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $93.77 +0.27
Pfizer Inc. (PFE.N) $29.11 -0.12
Merck & Co., Inc. (MRK.N) $48.58 +0.41
Sanofi SA (SASY.PA) €76.85 -3.32
AstraZeneca plc (AZN.L) 3,334.00p -1.00
GlaxoSmithKline plc (GSK.L) 1,712.50p +28.50
Eli Lilly & Co. (LLY.N) $53.50 +0.39

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$58.00
Provider: Stock Traders Daily
$495.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks